Key points are not available for this paper at this time.
We propose that a high Genomic Index determined by comparative genomic hybridization from formalin-fixed, paraffin-embedded samples could be used to identify AFIP intermediate-risk patients who would benefit from imatinib therapy.
Lagarde et al. (Tue,) studied this question.